What is the safest first‑line treatment for vaginal candidiasis in a woman at 14 weeks gestation?

Treatment of Vaginal Yeast Infection at 14 Weeks Gestation

Use a 7-day course of topical azole antifungal therapy—specifically clotrimazole 1% cream (5g intravaginally daily) or miconazole 2% cream (5g intravaginally daily)—as the only safe and effective first-line treatment for vaginal candidiasis at 14 weeks pregnancy. 1, 2

Why Topical Azoles Are the Only Option

• Oral fluconazole is absolutely contraindicated throughout pregnancy, including at 14 weeks gestation, due to documented teratogenic risks including spontaneous abortion, craniofacial defects (craniosynostosis), cardiac malformations, and skeletal abnormalities collectively termed "fluconazole embryopathy." 1, 2

• The CDC and ACOG explicitly state that only topical azole therapies should be used during pregnancy, despite the convenience of oral agents used in non-pregnant women. 3, 1, 2

• The teratogenic warnings apply exclusively to systemic (oral) azole formulations; topical clotrimazole and miconazole have no restrictions on first-trimester use and are considered safe throughout pregnancy. 1

Specific Treatment Regimens (Choose One)

The CDC recommends any of the following topical azole options 1, 2:

• Clotrimazole 1% cream: 5g intravaginally for 7–14 days
• Clotrimazole 100mg vaginal tablet: One tablet daily for 7 days
• Miconazole 2% cream: 5g intravaginally for 7 days
• Miconazole 100mg vaginal suppository: One suppository daily for 7 days
• Terconazole 0.4% cream: 5g intravaginally for 7 days

Why 7 Days Is Critical in Pregnancy

• Seven-day regimens achieve 80–90% cure rates in pregnant women, significantly outperforming the shorter 1- or 3-day courses commonly used in non-pregnant patients. 1, 4, 5

• A Cochrane review demonstrated that 4-day treatment courses were significantly less effective than 7-day courses during pregnancy (OR 11.7,95% CI 4.21–29.15), though 7-day and 14-day courses showed equivalent efficacy. 4

• The hormonal milieu of pregnancy increases Candida colonization and makes infections more difficult to eradicate, necessitating longer treatment duration. 3, 1

When to Extend Treatment Duration

• For severe vulvovaginitis (extensive erythema, edema, excoriation, or vulvar fissures), extend topical azole therapy to 7–14 days rather than stopping at 7 days. 1

• If symptoms persist after completing a 7-day course, suspect non-albicans Candida species (particularly C. glabrata) and repeat treatment with a 7–14 day course of an alternative topical azole. 1

Common Pitfalls to Avoid

• Do not use nystatin as first-line therapy—topical azoles are significantly more effective, with 80–90% cure rates compared to lower efficacy with nystatin. 2, 4

• Do not treat asymptomatic colonization: 10–20% of women harbor Candida without symptoms, and treatment is not indicated unless the patient is symptomatic. 1, 2

• Do not routinely treat sexual partners—vaginal candidiasis is not sexually transmitted. Partners should only receive topical antifungal treatment if they have symptomatic balanitis (penile erythema with pruritus). 3, 1, 2

Confirming the Diagnosis

Before initiating treatment, confirm the diagnosis by identifying 1, 2:

• Typical symptoms: Vulvar pruritus, white vaginal discharge, vaginal soreness, vulvar burning, dyspareunia, or external dysuria
• Normal vaginal pH ≤ 4.5 (elevated pH suggests bacterial vaginosis or trichomoniasis instead)
• Microscopy showing yeast or pseudohyphae on wet mount with 10% KOH, or positive culture for Candida species

Follow-Up and Treatment Failure

• Follow-up is unnecessary if symptoms resolve after completing the 7-day course. 1

• If symptoms persist, consider alternative diagnoses (bacterial vaginosis, trichomoniasis, contact dermatitis) or non-albicans Candida species requiring longer treatment. 1

• Even with suspected azole resistance, continue topical azole therapy—the CDC advises against escalating to boric acid (contraindicated in pregnancy) or oral fluconazole. 1

What About Systemic Therapy?

• If systemic antifungal therapy were absolutely necessary for life-threatening invasive fungal infection (not applicable to vaginal candidiasis), intravenous amphotericin B is the only safe systemic option during pregnancy. 1, 6, 7

• Amphotericin B has the most extensive safety data in pregnancy with no reports of teratogenesis, but it is reserved exclusively for severe systemic mycoses, not vaginal infections. 6, 7